Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Expected to Post Q3 2023 Earnings of ($0.39) Per Share

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) – Analysts at Northland Capmk decreased their Q3 2023 EPS estimates for Cardio Diagnostics in a research note issued on Thursday, September 7th. Northland Capmk analyst C. Byrnes now expects that the company will post earnings per share of ($0.39) for the quarter, down from their prior estimate of ($0.21). The consensus estimate for Cardio Diagnostics’ current full-year earnings is ($0.75) per share. Northland Capmk also issued estimates for Cardio Diagnostics’ Q4 2023 earnings at ($0.40) EPS and FY2023 earnings at ($1.30) EPS.

Separately, Northland Securities initiated coverage on shares of Cardio Diagnostics in a research note on Monday, May 22nd. They issued an “outperform” rating for the company.

Cardio Diagnostics Price Performance

CDIO stock opened at $0.44 on Monday. Cardio Diagnostics has a 1 year low of $0.32 and a 1 year high of $10.25. The company’s 50-day moving average is $0.92 and its 200-day moving average is $2.02.

Institutional Trading of Cardio Diagnostics

A number of hedge funds have recently bought and sold shares of the business. Prelude Capital Management LLC bought a new position in Cardio Diagnostics during the second quarter valued at about $131,000. State Street Corp purchased a new position in shares of Cardio Diagnostics during the 1st quarter valued at $163,000. Geode Capital Management LLC bought a new stake in Cardio Diagnostics in the 1st quarter valued at about $290,000. Finally, Bank of America Corp DE purchased a new stake in Cardio Diagnostics during the first quarter valued at about $59,000. 3.46% of the stock is currently owned by institutional investors.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc, an artificial intelligence-powered precision cardiovascular medicine company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.